Wegovy's success in reducing cardio risk is 'an important win,' and a 'best-case scenario,' say Wolfe analysts

The success of Novo Nordisk’s Wegovy in reducing cardiovascular events in obese adults is an important win for the obesity category with positive...

Related Keywords

Tim Anderson ,Eli Lilly Co ,Wolfe Research ,Novo Nordisk ,Eli Lilly ,Article Normal ,Pharmaceuticals ,Corporate Industrial News ,Eli Lilly Amp Co ,Rally ,Novo Nordiskas Adr ,Nvo ,Novo Nordiskas Series B ,Dk Novo B ,Corporate ,Industrial News ,